The company has already received the emergency use authorization (EUA) from the Drug Controller General of India (DCGI) for ZyCoV-D to be administered in three doses on August 20
The filing includes data from PROVENT Phase III trial showing 77% reduction in risk of developing symptomatic Covid-19 with a long-acting antibody combination (non-vaccine)
CuraTeQ Biologics is on track for filing a second oncology biosimilar
The purchaser is a part of the portfolio companies of PE firm True North. The said transaction is not a related party transaction.
Cephalosporin is a bactericidal, broad-spectrum, and P-lactam antibiotic originally derived from the fungus Acremonium, which is used to treat bacterial infections such as pneumonia, skin infections, ear infection, strep throat, staph infections, tonsillitis, bronchitis among others
The company said in a regulatory filing that it was confident of addressing the observations satisfactorily
The board has approved the settlement of US $ 248 million towards Direct Purchaser group and Retailer Opt-Out group subject to court approval
The revenues and profits derived from the new subsidiary will be consolidated in the parent company
The agreement is to develop, manufacture and commercialise biosimilars for the global market.
Turnover of API division of ISLL stood at Rs 856.58 crore
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
